Key Points
- BioNTech CEO Ugur Sahin sold 21,000 shares for approximately $2.03 million at an average price of $96.81, reducing his direct holdings by 19.41%. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Sahin has made multiple recent sales, including 72,000 shares on October 5, bringing the reported sales over the broader period to several hundred thousand shares.
- BioNTech shares opened at $95.83 and were down 1.9%; the company recently missed quarterly earnings and revenue estimates, while analysts maintained a “Moderate Buy” consensus with an average price target of $126.
BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 21,000 shares of the business's stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $96.81, for a total transaction of $2,033,010.00. Following the completion of the sale, the chief executive officer directly owned 87,209 shares of the company's stock, valued at approximately $8,442,703.29. The trade was a 19.41% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ugur Sahin also recently made the following trade(s):
- On Monday, October 5th, Ugur Sahin sold 72,000 shares of BioNTech stock. The shares were sold at an average price of $97.23, for a total transaction of $7,000,560.00.
- On Thursday, October 1st, Ugur Sahin sold 17,000 shares of BioNTech stock. The stock was sold at an average price of $97.46, for a total transaction of $1,656,820.00.
- On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The stock was sold at an average price of $98.12, for a total transaction of $3,139,840.00.
- On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.47, for a total transaction of $3,347,980.00.
- On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The shares were sold at an average price of $98.69, for a total transaction of $2,664,630.00.
- On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The stock was sold at an average price of $98.99, for a total value of $3,860,610.00.
- On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total value of $2,982,000.00.
- On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The shares were sold at an average price of $100.72, for a total value of $4,633,120.00.
- On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The shares were sold at an average price of $97.81, for a total value of $3,227,730.00.
- On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $96.22, for a total value of $2,886,600.00.
BioNTech Stock Down 1.9%
Shares of BNTX opened at $95.83 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. BioNTech SE Sponsored ADR has a one year low of $79.52 and a one year high of $124.00. The stock has a market capitalization of $24.23 billion, a price-to-earnings ratio of -12.24 and a beta of 1.25. The stock has a 50 day moving average price of $99.01 and a 200 day moving average price of $95.10.
BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The firm had revenue of $122.31 million during the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The firm's revenue for the quarter was down 59.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.60) earnings per share. Equities research analysts forecast that BioNTech SE Sponsored ADR will post -6.37 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on BNTX. Citigroup lowered their price target on shares of BioNTech from $130.00 to $125.00 and set a "buy" rating on the stock in a research report on Wednesday, August 5th. Canaccord Genuity Group lowered their target price on BioNTech from $142.00 to $136.00 and set a "buy" rating on the stock in a report on Monday, August 31st. Wall Street Zen lowered BioNTech from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. Morgan Stanley cut their price target on BioNTech from $126.00 to $119.00 and set an "overweight" rating for the company in a report on Wednesday, July 8th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of BioNTech in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $126.00.
Read Our Latest Stock Report on BioNTech
Institutional Trading of BioNTech
Several institutional investors have recently added to or reduced their stakes in BNTX. Hsbc Holdings PLC acquired a new stake in shares of BioNTech in the fourth quarter valued at $4,969,000. Bank of America Corp DE lifted its stake in BioNTech by 22.6% during the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company's stock worth $80,261,000 after acquiring an additional 166,432 shares in the last quarter. Amundi lifted its stake in BioNTech by 24.5% during the 1st quarter. Amundi now owns 129,513 shares of the company's stock worth $11,511,000 after acquiring an additional 25,506 shares in the last quarter. Headlands Technologies LLC purchased a new position in BioNTech during the 2nd quarter valued at about $2,520,000. Finally, Flossbach Von Storch SE purchased a new position in BioNTech during the 2nd quarter valued at about $207,142,000. Institutional investors and hedge funds own 15.52% of the company's stock.
BioNTech Company Profile
(
Get Free Report)
BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company's research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.
BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
